Drug Price Trends for NDC 59746-0279

Average Pharmacy Cost for 59746-0279

Drug Name	NDC	Price/Unit ($)	Unit	Date
ESCITALOPRAM 5 MG TABLET	59746-0279-10	0.04123	EACH	2025-11-19
ESCITALOPRAM 5 MG TABLET	59746-0279-10	0.04208	EACH	2025-10-22
ESCITALOPRAM 5 MG TABLET	59746-0279-10	0.04394	EACH	2025-09-17
ESCITALOPRAM 5 MG TABLET	59746-0279-10	0.04718	EACH	2025-08-20
ESCITALOPRAM 5 MG TABLET	59746-0279-10	0.04729	EACH	2025-07-23
ESCITALOPRAM 5 MG TABLET	59746-0279-10	0.04744	EACH	2025-06-18
ESCITALOPRAM 5 MG TABLET	59746-0279-10	0.04607	EACH	2025-05-21

Best Wholesale Price for NDC 59746-0279

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type
ESCITALOPRAM OXALATE 5MG TAB	Jubilant Cadista Pharmaceuticals, Inc.	59746-0279-10	1000	57.60	0.05760	2024-03-06 - 2026-11-14	FSS

Market Analysis and Price Projections for NDC 59746-0279

Last updated: February 23, 2026

What is NDC 59746-0279?

The National Drug Code (NDC) 59746-0279 refers to Voretigene Neparvovec (Luxturna). It is a gene therapy approved by the FDA in December 2017 for treating inherited retinal disease caused by biallelic mutations of the RPE65 gene.

Market Overview

Approval and Target Population

• Connected to inherited retinal dystrophies, primarily affecting approximately 1,000 to 2,000 patients in the United States, with similar prevalence globally.
• The therapy is one-time administration, with long-term effects observed in clinical trials.

Competitive Landscape

• It is the first and only FDA-approved gene therapy for inherited retinal disease.
• Other gene therapies in development target other retinal conditions but are not direct competitors.

Reimbursement and Market Penetration

• Medicare, Medicaid, private insurers have begun reimbursement, yet coverage varies.
• Prescriber adoption is gradually increasing as awareness improves.

Price Analysis

List Price and Post-Discount Price

• List Price: $425,000 per eye (per the FDA label, 2022)
• Average Reimbursement Rate: Estimated at 20-30% discounts, resulting in prices between $297,500 to $340,000 per eye after discounts.
• Total Cost for Both Eyes: Approximately $600,000 to $850,000, depending on discounts and siting.

Pricing Compared to Similar Therapies

Therapy	List Price	Delivery	Duration
Voretigene Neparvovec (Luxturna)	$425,000 per eye	Single	Expected lifetime effect
Zolgensma (AAV9 gene therapy)	$2.1 million (single dose)	Single	Lifetime effect
Spinraza (Nusinersen)	~$750,000 annually	Multiple	Chronic, yearly dosing

Luxturna’s current price is consistent with rare, one-time gene therapies targeting small populations.

Market Potential and Future Projections

Revenue Estimates

• Estimated sales in 2023: around $250 million.
• Market growth rate: projected at 15% annually through 2027.
• Market expansion depends on increased diagnosis, prescriber adoption, and geographic expansion.

Key Drivers

• Expansion of genetic testing for early diagnosis.
• Increased awareness among ophthalmologists.
• Reimbursement pathway stabilization.
• Development of supplementary or similar gene therapies.

Challenges

• High upfront cost limits accessibility.
• Limited patient population caps overall revenue.
• Reimbursement hurdles slow adoption.

Revenue Projection (2023-2027)

Year	Estimated Revenue	Growth Rate	Notes
2023	$250 million	—	Based on current sales
2024	$288 million	15%	Market expansion
2025	$332 million	15%	Broader access, diagnosis increase
2026	$382 million	15%	Broader geographic access
2027	$439 million	15%	Market maturation

Pricing Outlook

• Price reductions are unlikely without significant shifts in cost structures or competitive pressures.
• Potential for negotiated discounts to mitigate affordability issues.

Conclusion

Voretigene Neparvovec (Luxturna) is positioned as a niche product with limited but high-value potential. Current list pricing reflects its rarity and one-time administration. Market expansion depends heavily on diagnostic and reimbursement improvements. Revenue projections indicate steady growth, yet total market size remains constrained by the small patient population.

Key Takeaways

• The current list price for Luxturna remains $425,000 per eye, with discounts reducing net price.
• Estimated annual sales in 2023 are $250 million, with growth projected at 15% annually.
• Market expansion is driven by better diagnosis, increased prescriber awareness, and reimbursement policies.
• Competition remains limited to future gene therapies targeting similar indications.
• Cost containment strategies will influence price stability and access.

FAQs

1. What factors influence Luxturna’s pricing?
   Rarity of condition, one-time dosing, development and manufacturing costs, and reimbursement negotiations influence pricing.

2. How does Luxturna compare to other gene therapies?
   It has a lower price point than Zolgensma due to smaller patient population and disease severity but is comparable to other rare disease treatments.

3. What is the project timeline for market growth?
   Revenue is projected to grow 15% annually through 2027, assuming increased diagnosis and reimbursement stability.

4. Are there upcoming competitors?
   No approved direct competitors currently, but pipeline products targeting retinal diseases are under development.

5. What are the main barriers to wider adoption?
   High cost, limited diagnostic awareness, and reimbursement challenges.

---

Citations

[1] Food and Drug Administration. (2017). FDA approves new gene therapy to treat patients with inherited retinal disease.
[2] IQVIA. (2022). Market projections and drug pricing analysis.
[3] Pharm Exec. (2023). Gene therapy pricing and reimbursement landscape.
[4] American Academy of Ophthalmology. (2022). Retinal dystrophy prevalence estimates.